Dublin, Feb. 20, 2017 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Proteomics - Technologies, Markets and Companies" to their offering.
This report describes and evaluates the proteomic technologies that will play an important role in drug discovery, molecular diagnostics and practice of medicine in the post-genomic era - the first decade of the 21st century.
Proteomics is providing a better understanding of pathomechanisms of human diseases. Analysis of different levels of gene expression in healthy and diseased tissues by proteomic approaches is as important as the detection of mutations and polymorphisms at the genomic level and may be of more value in designing a rational therapy. Protein distribution / characterization in body tissues and fluids, in health as well as in disease, is the basis of the use of proteomic technologies for molecular diagnostics.
Proteomics will play an important role in medicine of the future which will be personalized and will combine diagnostics with therapeutics. Important areas of application include cancer (oncoproteomics) and neurological disorders (neuroproteomics). The text is supplemented with 44 tables, 28 figures and over 500 selected references from the literature.
The number of companies involved in proteomics has increased remarkably during the past few years. More than 300 companies have been identified to be involved in proteomics and 224 of these are profiled in the report with 456 collaborations.
The markets for proteomic technologies are difficult to estimate as they are not distinct but overlap with those of genomics, gene expression, high throughput screening, drug discovery and molecular diagnostics. Markets for proteomic technologies are analyzed for the year 2016 and are projected to years 2021 and 2026. The largest expansion will be in bioinformatics and protein biochip technologies. Important areas of application are cancer and neurological disorders
Key Topics Covered:
Part I: Technologies & Markets
Executive Summary
1. Basics of Proteomics
2. Proteomic Technologies
3. Protein biochip technology
4. Bioinformatics in Relation to Proteomics
5. Research in Proteomics
6. Pharmaceutical Applications of Proteomics
7. Application of Proteomics in Human Healthcare
8. Oncoproteomics
9. Neuroproteomics
10. Proteomics Markets
11. Future of Proteomics
12. References
Part II: Companies
11. Companies involved in developing proteomics
For more information about this report visit http://www.researchandmarkets.com/research/n9q3zl/proteomics
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Proteomics


San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Baker Hughes Sells Waygate Technologies to Hexagon for $1.45 Billion
Chinese Cars in Europe: Consumer Trust Is Shifting Fast
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Bill Ackman Eyes New Fund to Bet Against Market Complacency
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 



